BIOGEN IDEC - Oral MS Landscape/ Additive news flow - Getting Better for BIIB
We reiterate our Outperform rating on Biogen Idec (BIIB) with a TP of $108 (WACC 8%) in light of recent news flow that has been favorable for BIIB. We expect this trend to continue in the upcoming months – conditional approval of Fampyra in the EU and positive outcome on PhIII, CONFIRM trial (head-to-head with Copaxone) of BG-12. For more detail, please read our report released on 24th June, 2011 on BIIB titled “Oral MS Landscape/ Additive news flow – Getting Better for BIIB”.
COMPANIES MENTIONED
Biogen Idec, BIIB
Biogen Idec, BIIB
